Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carcinoid heart disease.

Alain M Bernheim1, Heidi M Connolly, Patricia A Pellikka

  • 1Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Current Treatment Options in Cardiovascular Medicine
|January 29, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical benefit of optimization of heart failure therapy after heart failure hospitalization in adults with CHD.

International journal of cardiology. Congenital heart disease·2026
Same author

Outcomes of liver resections for neuroendocrine tumor liver metastases in carcinoid heart disease.

Journal of neuroendocrinology·2026
Same author

Discrimination of atrial fibrillation burden using cardiac magnetic resonance imaging.

Heart rhythm O2·2026
Same author

Reoperations after the Ross procedure: Techniques, complexity, and outcomes.

JTCVS structural and endovascular·2026
Same author

Prognostic Value of Left Ventricular Contractility Index in Patients with Coarctation of Aorta and Preserved Ejection Fraction.

American heart journal·2026
Same author

Outcome of Heart Failure Therapy in Adults With Congenitally Corrected Transposition of Great Arteries.

JACC. Heart failure·2026
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
See all related articles

Carcinoid heart disease requires integrated care. Key treatments include somatostatin analogues, surgical debulking of liver metastases, and valve replacement surgery for severe cardiac issues.

Area of Science:

  • Oncology
  • Cardiology
  • Endocrinology

Background:

  • Carcinoid heart disease necessitates a multidisciplinary approach, balancing systemic disease treatment with cardiac management.
  • The endocrine syndrome associated with carcinoid tumors can be managed with somatostatin analogues.
  • Chemotherapy has limited efficacy for carcinoid tumors.

Purpose of the Study:

  • To outline the integrated management strategies for patients with carcinoid heart disease.
  • To highlight the roles of various treatment modalities in addressing both the systemic and cardiac aspects of the disease.

Main Methods:

  • Review of current therapeutic strategies for carcinoid syndrome and carcinoid heart disease.
  • Discussion of surgical interventions including hepatic resection and valve replacement.

Related Experiment Videos

  • Evaluation of medical management including somatostatin analogues.

    • Main Results:

    • Hepatic resection of metastases is the preferred treatment for liver involvement, aiming for >90% removal.
    • Hepatic artery embolization is an alternative for unresectable metastases.
    • Valve replacement surgery can significantly improve outcomes in severe cardiac cases with controlled systemic disease.

    Conclusions:

    • Integrated, multidisciplinary care is essential for managing carcinoid heart disease.
    • Surgical debulking of liver metastases and valve replacement surgery are critical interventions for improving patient prognosis and quality of life.